Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

Excerpt from the Press Release:

WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of a randomized, double-blind, vehicle-controlled, multicenter Phase 3 clinical study to evaluate the safety and efficacy of Ameluz^® and BF-RhodoLED^® XL in the field-directed treatment of actinic keratosis (AK) on the extremities, neck and trunk. The study is being managed by Biofrontera Bioscience GmbH.

This past weekend Biofrontera held an Investigator Meeting to train clinical investigators on the protocol for this photodynamic therapy (PDT) study and prepare for site initiation. Initially 11 clinical trial sites in the U.S. will participate, enrolling approximately 165 patients stratified by body region. This study will utilize Biofrontera’s new RhodoLED^® XL, a red-light lamp approved by the U.S. Food and Drug Administration (FDA) for use in PDT in combination with Ameluz^® (Ameluz^®-PDT) for the treatment of mild-to-moderate actinic keratosis. This lamp allows for the illumination of a larger surface area, thereby enabling simultaneous treatment of AK lesions that are distant from one another.

“This Phase 3 clinical study supports our strategy to gain market share by expanding the label for Ameluz^®-PDT beyond the treatment of AK on the face and scalp. Additionally, by employing the larger RhodoLED^® XL lamp investigators can target more lesions and reinforce the lamp’s utility ahead of commercial launch,” said Erica Monaco, Chief Executive Officer of Biofrontera Inc.

Click the button below to read the entire Press Release:

Continue Reading The Press Release